Longevity Research Roundup: Epigenetics, Peptides & Lifestyle (August 2026)
This week's roundup features GLP-1s and novel peptides influencing epigenetic clocks, alongside critical insights into optimising exercise and diet.
# Longevity Research Roundup: Epigenetics, Peptides & Lifestyle (August 2026)
The pursuit of a longer, healthier life continues to accelerate, with breakthroughs emerging at a relentless pace. This week's roundup brings together compelling human data and significant preclinical findings that are shaping our understanding of ageing. From the surprising anti-ageing signals of GLP-1 agonists to novel small molecules that roll back biological clocks, and even a fresh look at optimising our lifestyle choices, the evidence is becoming clearer. We're moving beyond mere correlation towards concrete interventions that promise tangible improvements to healthspan.
Semaglutide Shows Epigenetic Age Slowing in HIV Patients
A recent re-analysis of a 32-week randomised trial involving 84 adults with HIV treated with semaglutide has delivered intriguing news. The GLP-1 treatment was found to significantly slow several epigenetic clocks of biological age compared with control groups [4, 6]. While the original trial focused on metabolic improvements, this exploratory analysis highlights a broader, systemic impact on the ageing process, independent of weight loss or glycaemic control. This is significant because it's one of the first human clinical datasets to show a GLP-1 agonist positively influencing validated biological age clocks, strengthening the case that these compounds may act as true geroprotectors, not just weight management tools. The improvements in inflammation, metabolic load, and adiposity linked to GLP-1s appear to translate into a slower pace of systemic ageing.
**What was found:** A re-analysis of an existing trial found that semaglutide treatment slowed DNA-methylation-based biological ageing in 84 adults with HIV over 32 weeks, beyond its effects on weight and blood sugar [4, 6].
**Sample size & effect:** 84 adults with HIV. Semaglutide reduced the pace of ageing and age estimates on multiple DNA-based clocks compared to controls.
**Why it matters:** This provides human clinical evidence that GLP-1 agonists might be genuine geroprotectors, suggesting that their metabolic benefits can translate into slower systemic ageing. For those considering metabolic interventions, it adds another layer to the potential benefits beyond weight and diabetes management. (See also: /legal/disclaimer)
**Actionable takeaway:** If you're managing metabolic syndrome, type 2 diabetes, or obesity, discuss GLP-1 agonists like semaglutide with your doctor. The potential to slow biological ageing is a compelling additional benefit beyond the widely recognised weight and glycaemic control. This adds another dimension to our previous coverage on GLP-1s.
PAI-1 Inhibitor TM5614 Reverses Biological Age by Years
One of the more eye-catching headlines this week concerns TM5614, an oral plasminogen activator inhibitor-1 (PAI-1) blocker. In a clinical trial involving 20 older adults, four months of TM5614 administration led to an average biological age reduction of approximately 2–3 years, as assessed by composite health markers and ageing clocks [5]. PAI-1 is a notorious molecule associated with senescence, inflammation, and blood clot formation; high genetic levels of PAI-1 are linked to shorter lifespans and increased cardiometabolic disease risk. This study provides the first-in-human interventional evidence that targeting PAI-1 can indeed move biological age clocks backward, firmly establishing PAI-1 as a serious druggable ageing pathway. What's particularly promising is that TM5614 is a small molecule, offering a different modality from the peptides we often discuss, positioning it firmly within the emerging class of precision geroprotectors.
**What was found:** Four months of oral TM5614, a PAI-1 blocker, reduced biological age by 2–3 years on average in 20 older adults, based on multiple health markers and ageing clocks [5].
**Sample size & effect:** 20 older adults. Average biological age reduction of 2–3 years over four months.
**Why it matters:** This is significant human evidence that targeting PAI-1, a key pro-inflammatory and pro-thrombotic protein, can reverse biological age. It highlights PAI-1 as a potent druggable target for ageing interventions. (See also: /legal/disclaimer)
**Actionable takeaway:** While TM5614 isn't widely available yet, understanding PAI-1's role is crucial. Individuals with elevated inflammatory markers or a history of cardiovascular issues might consider discussing PAI-1 levels with their clinician. Lifestyle interventions that reduce inflammation could indirectly help, but this drug offers a direct hit. Our editorial take is that this is one to watch closely.
Broader Implications of Semaglutide and Biological Ageing
The narrative around GLP-1s continues to evolve. Beyond the HIV-specific findings, the broader context of semaglutide trials suggests that these drugs may slow multiple measures of biological ageing in general populations [4, 6]. The improvements in inflammation, liver fat, and insulin resistance that GLP-1s induce are thought to be the underlying mechanisms explaining these clock-level effects. For longevity practitioners and individuals, this means GLP-1s are potentially valuable not just for managing obesity and diabetes, but also for modulating the rate of ageing, especially in those with high-risk metabolic phenotypes, such as fatty liver or severe insulin resistance. This shift also highlights an important methodological trend: existing clinical drug trials are now being re-analysed with advanced biological age clocks, rapidly identifying new geroprotectors from established pharmacotherapies.
**What was found:** GLP-1 agonists like semaglutide show potential to slow various biological ageing measures beyond their effects in HIV patients, mediated by improvements in inflammation, liver fat, and insulin resistance [4, 6].
**Sample size & effect:** Re-analysis of multiple trials. GLP-1-mediated improvements are linked to positive effects on biological clocks.
**Why it matters:** It expands the rationale for using GLP-1s beyond their primary indications, positioning them as potential anti-ageing agents, particularly for those with metabolic risks. This is a powerful example of repurposing existing drugs for longevity. (See also: /legal/disclaimer)
**Actionable takeaway:** If you are at risk for metabolic disease or have been prescribed a GLP-1 agonist, recognise that you might be gaining more than just weight control. This suggests a systemic benefit to healthspan that is worth discussing with your healthcare provider. For more on metabolic control, see our glucose control protocol.
FAXAge Trial: Fasting and Exercise for Ageing Intervention
The FAXAge study is a notable randomised, controlled clinical trial protocol designed to systematically investigate whether combining intermittent fasting with structured exercise can slow human ageing. It aims to use biological age clocks and functional measures as primary endpoints [5]. The study will rigorously assess the impact on DNA-methylation clocks, metabolic and inflammatory markers, and physical function. Much of the evidence for fasting and exercise as ageing modifiers has historically come from observational studies or relied on surrogate markers. FAXAge's robust interventional design, with its multi-omic ageing endpoints, is set to provide high-quality data. This will help us quantify the effect sizes of lifestyle interventions relative to pharmacological geroprotectors, informing how we prioritise and stack our interventions.
**What was found:** The FAXAge study is a new randomised clinical trial protocol designed to test if intermittent fasting combined with structured exercise can slow human ageing, using biological age clocks and functional measures as endpoints [5].
**Sample size & effect:** A protocol-stage trial, so no data yet. The study aims to systematically measure effects on DNA-methylation clocks, metabolic markers, inflammatory markers, and physical function.
**Why it matters:** This trial will provide rigorous, interventional evidence on the combined effects of fasting and exercise on ageing, helping to quantify their impact against pharmacological interventions. This is crucial for building evidence-based protocols.
**Actionable takeaway:** While we await the results, continue to integrate intermittent fasting (if suitable for you) and regular exercise into your routine. This study reinforces the importance of foundational lifestyle practices. For more on structuring your exercise, refer to our Zone 2 Cardio and Muscle Preservation protocols.
Piceatannol: A Next-Generation Polyphenol with Senolytic-Like Effects
Moving into the realm of nutraceuticals, piceatannol, a polyphenol related to resveratrol, has shown impressive senolytic-like effects in ageing mouse models. Supplementation with piceatannol improved motor coordination and spatial memory in mice, alongside a reduction in senescent cell burden in kidney and heart tissues [8]. This reduction in senescent cells correlated with lower systemic inflammatory proteins, indicating a senomorphic or mild senolytic action. Interestingly, a completed human trial using 10 mg/day of piceatannol in healthy women demonstrated improved skin hydration and reduced wrinkles, with a good safety profile at that dose [8]. This multi-organ impact, coupled with functional benefits and histological evidence of senescent cell reduction, elevates piceatannol into the senotherapeutic supplement category. It appears to offer stronger senescence-targeting and anti-inflammatory properties than resveratrol in preclinical work, making it a candidate to consider alongside other geroprotective supplements like spermidine and urolithin A.
**What was found:** Piceatannol, a polyphenol, improved motor coordination and spatial memory, and reduced senescent cell burden in ageing mice. A human trial showed improved skin hydration and reduced wrinkles at 10 mg/day [8].
**Sample size & effect:** Ageing mice showed functional and histological improvements. Human trial in healthy women (number not specified) showed skin benefits.
**Why it matters:** This positions piceatannol as a promising senotherapeutic supplement, mechanistically similar to resveratrol but potentially with more potent senescence-targeting effects. It’s an exciting addition to the growing list of compounds that target cellular senescence.
**Actionable takeaway:** Consider exploring piceatannol as an adjunct to your current supplement stack, particularly if you’re interested in targeting senescent cells and inflammation. As with any new supplement, start with a low dose and monitor your response. For sourcing, it's worth checking specialist retailers like those stocking health-focussed supplements in the UK.
Modified Mediterranean Diet Extends Healthspan in Mice
Researchers at the University of Southern California have tested a modified Mediterranean-style diet in ageing mice, yielding promising results for healthspan extension. This diet was primarily plant and fish-based, with low total protein and carefully restricted methionine [13]. The mice on this regimen experienced increased healthspan, reduced body fat, and lower frailty scores, all without signs of malnutrition. Methionine restriction is a well-established lifespan-extending intervention in rodents, but often challenging to implement in practice. This study demonstrates that a real-world dietary pattern, akin to a low-protein Mediterranean diet, can capture much of that benefit, with tangible functional endpoints like frailty reduction. For human longevity, this supports the adoption of periodic or chronic low-protein, plant-forward eating patterns – especially in mid-life – as a healthspan-enhancing strategy. It also provides a strong mechanistic rationale for combining protein modulation with resistance training to counteract potential sarcopenia.
**What was found:** A modified Mediterranean-style diet (low protein, restricted methionine) in ageing mice led to increased healthspan, reduced body fat, and lower frailty scores without malnutrition [13].
**Sample size & effect:** Ageing mice (number not specified). Increased healthspan, reduced body fat, lower frailty scores.
**Why it matters:** This demonstrates that a practical, real-world dietary pattern can replicate the longevity benefits of methionine restriction, offering a powerful dietary strategy for humans to improve healthspan.
**Actionable takeaway:** Consider incorporating more plant and fish-based meals into your diet, aiming for periods of lower protein intake (e.g., occasional vegetarian days) and being mindful of methionine sources. This supports the general move towards more plant-forward eating, provided you maintain adequate protein for muscle mass, especially with increasing age.
Optimal Resistance Training Dose for Longevity
A large cohort study tracking 147,000 adults over 30 years has provided a surprisingly precise 'dose' for resistance training to maximise longevity benefits. The optimal range was identified as 90–119 minutes per week of strength training, which was associated with a significant reduction in all-cause mortality and deaths from neurological diseases [5, 7]. This finding is invaluable for protocol design, suggesting that around 15–20 minutes per day of strength training captures most of the survival benefit. It strongly supports pairing zone-2 or VO₂-max cardiovascular work (already a cornerstone of our Healthspan Foundation Protocol) with approximately two hours per week of dedicated strength training. This dual approach helps optimise both sarcopenia protection and brain longevity.
**What was found:** A 30-year cohort study of 147,000 adults found that 90–119 minutes of weekly strength training was associated with a significant reduction in all-cause mortality and deaths from neurological diseases [5, 7].
**Sample size & effect:** 147,000 adults over 30 years. Optimal range of 90–119 minutes/week of strength training significantly reduced mortality.
**Why it matters:** This provides a clear, actionable target for the 'dose' of resistance training needed for maximal longevity benefits, making it easier to integrate into a comprehensive healthspan strategy.
**Actionable takeaway:** Aim for 90–119 minutes of resistance training per week, spread across 2-3 sessions. This specific target can help you structure your exercise routine effectively for long-term health. Don't neglect your muscle preservation.
Tyrosine Levels as a Mortality Risk Biomarker
An interesting finding from a large study indicates that higher circulating levels of the amino acid tyrosine are associated with shorter lifespans in men, with an estimated loss of close to one year of life expectancy compared to those with lower levels [7]. The analysis links elevated tyrosine to cardiometabolic and neurological risk, though causality remains to be firmly established. This positions circulating tyrosine as a potential ageing-related biomarker, possibly reflecting aspects of protein intake quality, catecholamine metabolism, or oxidative stress. For longevity enthusiasts, this raises questions about excessive tyrosine supplementation, sometimes used for cognitive enhancement, and suggests that comprehensive amino-acid profiling could refine dietary protocols and peptide and supplement stacks.
**What was found:** A large study found that men with higher blood levels of tyrosine had shorter lifespans, with an estimated loss of nearly one year of life expectancy [7].
**Sample size & effect:** Large study (number not specified). Higher tyrosine levels linked to shorter lifespan and ~1-year loss of life expectancy in men.
**Why it matters:** This identifies tyrosine as a potential ageing biomarker, suggesting that imbalances in amino acid metabolism could impact longevity. It also prompts caution regarding indiscriminate high-dose amino acid supplementation.
**Actionable takeaway:** If you use tyrosine as a supplement, consider moderation and consult your healthcare provider about amino acid profiling, especially if you have existing cardiometabolic or neurological concerns. This is a nuanced area, and more isn't always better.
Rare Anti-Inflammatory Variant in Long-Lived Families
A study examining long-lived families has identified rare genetic variants that appear to contribute to extended healthspan. One standout mutation was found to temper inflammation, potentially delaying age-related diseases and extending healthy years of life [9]. This strengthens the concept that chronic, low-grade inflammation – often termed “inflammaging” – is not merely a correlate of ageing but is causally modulated by specific genetic architectures. For those interested in personalised longevity strategies, such variants offer targets for computational drug design, polygenic risk scoring, and tailored anti-inflammatory interventions, including PAI-1 inhibitors (like TM5614 discussed earlier), IL-6/CRP-targeting strategies, and senolytics.
**What was found:** A study of long-lived families identified rare genetic variants, including one that tempers inflammation, associated with extended healthspan and delayed age-related disease [9].
**Sample size & effect:** Not specified, but involved long-lived families. Genetic variant linked to anti-inflammatory effects and extended healthy lifespan.
**Why it matters:** This reinforces the causal role of chronic inflammation in ageing and highlights specific genetic pathways as targets for future anti-ageing therapies, offering potential avenues for precision medicine.
**Actionable takeaway:** While genetic variants aren't something we can change directly, understanding their impact underscores the importance of managing inflammation through diet, exercise, and potentially targeted supplements or future medications. Anti-inflammatory lifestyle choices are a broadly applicable strategy.
NAD+ Pathway Responsiveness: A Multi-Organ View
Recent discussions in ageing biology highlight a nuanced understanding of the NAD+ pathway. A cross-organ ageing map indicates that the NAD+ pathway may be selectively responsive to intervention in specific tissues, rather than showing a global age-related decline in all human tissues [2, 16]. This reframes the role of NAD+ precursors like NMN and NR; they are increasingly seen as tissue-specific metabolic tools, not universal ageing fixes. Commentary notes that new human data suggest NAD levels do not consistently decline with age in blood, and while NR supplementation increases NAD+ in some tissues, its effects on lifespan and biological age have been modest so far [10, 16]. This multi-organ perspective is vital for a more targeted approach to longevity interventions, suggesting that future AI models might help determine which organ's NAD+ or mitochondrial function to prioritise for a given individual.
**What was found:** A multi-organ ageing map indicates that NAD+ pathway responsiveness to intervention is tissue-specific, and blood NAD+ levels don't consistently decline with age in humans. NR supplementation's effects on lifespan and biological age have been modest [2, 10, 16].
**Sample size & effect:** Not specified, but based on multi-organ mapping and human data. NAD+ precursors are seen as tissue-specific tools, with modest global effects.
**Why it matters:** This provides a more precise view of NAD+ biology, shifting focus from a universal solution to tissue-specific optimisation. It also calls for more nuanced research into NAD+ precursors like NMN.
**Actionable takeaway:** While NAD+ precursors remain popular, recognise that their effects might be more localised than previously thought. If you're supplementing with NMN or NR, consider combining it with other interventions targeting specific tissues or pathways, and focus on fundamental practices that boost mitochondrial health across the board (e.g., exercise). Our mitochondrial optimisation protocol delves deeper.
Psilocybin and Neuroplasticity in Older Adults
In a fascinating development, the Berkeley Center for the Science of Psychedelics is recruiting healthy adults aged 60–85 for a trial investigating psilocybin's potential to enhance neuroplasticity and successful ageing [18]. Participants will receive a 1–30 mg dose of psilocybin and undergo three MRI sessions to quantify brain-level changes before and after the intervention. This trial directly addresses whether acute psychedelic-induced neuroplasticity can contribute to successful ageing, particularly through changes in brain connectivity, cognitive resilience, and emotional regulation. For longevity practices, this opens a potential avenue for regulated, periodic neuroplasticity interventions that could be layered onto standard geroprotectors, with MRI endpoints that may eventually integrate into AI models of brain ageing. This is a very early-stage area of research with significant regulatory hurdles, particularly in the UK, but the scientific implications are profound.
**What was found:** A randomised trial is recruiting healthy adults aged 60–85 to test if psilocybin enhances neuroplasticity and successful ageing, using MRI to quantify brain changes [18].
**Sample size & effect:** Recruitment stage. Participants will receive 1–30 mg psilocybin. Expected effects on brain connectivity, cognitive resilience, and emotional regulation.
**Why it matters:** This explores a novel approach to brain ageing, investigating whether psychedelics can induce neuroplasticity that contributes to cognitive health in older adults. It opens a new frontier for cognitive enhancement.
**Actionable takeaway:** This research is highly experimental and not for self-experimentation. Stay informed about the results of this and similar regulated trials. If positive, it may eventually lead to new, supervised therapeutic options for brain health and ageing. (See also: /legal/disclaimer)
Gaps we are watching
While this fortnight has provided substantial insights, several areas warrant continued close attention. Firstly, the long-term safety and efficacy of novel small molecules like TM5614 need further large-scale human trials. The early signals are incredibly promising, but widespread adoption requires comprehensive data on chronic use. Secondly, the integration of AI with personalised longevity protocols is still in its infancy. While multi-organ ageing maps and biomarker profiling are advancing rapidly, the sophisticated AI models needed to translate this data into truly bespoke, actionable plans for individuals are largely conceptual. We are particularly keen to see how the results from the FAXAge trial help quantify lifestyle interventions against pharmacological ones, allowing for more precise 'dosing' of fasting and exercise. Finally, the role of specific amino acid ratios and their impact on longevity, beyond general protein intake, is an emerging field. The tyrosine finding hints at a complex interplay that warrants much deeper investigation before specific amino acid interventions can be recommended broadly.
Bottom line
This past fortnight has truly underscored a shift in longevity research: from theoretical mechanisms to actionable, human-validated interventions. The evidence that GLP-1 agonists can slow biological ageing, combined with the exciting promise of PAI-1 inhibitors like TM5614, suggests we are entering an era where pharmacological tools can genuinely influence our intrinsic ageing rate. These are powerful signals for those with metabolic dysfunction, offering more than just symptomatic relief. Simultaneously, the precise dosing recommendations for resistance training, along with compelling data on modified Mediterranean diets, reinforce that foundational lifestyle choices remain paramount. While AI integration and certain novel compounds are still emerging, the confluence of targeted pharmacotherapy and optimised lifestyle presents a formidable strategy for extending healthspan. For now, prioritise those 90-119 minutes of weekly strength training, consider a plant-forward diet, and, if appropriate, discuss GLP-1 options with your doctor. Skip indiscriminate high-dose amino acid supplementation until more is known about specific biomarker profiles.